Skip to main content
  • Semaglutide Shows Promise in Improving Functional Status, Reducing Symptoms in Obesity-Related HFpEF Patients

    Semaglutide appears to be an effective treatment for improving functional status, reducing symptoms, and improving weight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), reports a new pooled analysis of trial data.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details